Association between antiplatelet therapy and cerebral microbleeds determined by susceptibility weighted imaging in stroke-free pupolation
Miaoxin Yu1, Yanan Jia2, Dandan Yang3, Runhua Zhang1, Yong Jiang1, Guitao Zhang1, Huiyu Qiao4, Hualu Han4, Rui Shen4, Zihan Ning4, Xihai Zhao4, and Gaifen Liu1
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases, Beijing, China, 2Department of Neurology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China, 3Department of Radiology, Beijing Geriatric Hospital, Beijing, China, 4Center for Biomedical Imaging Research, Department of Biomedical Engineering, Tsinghua University, Beijing, China
In this cross-sectional, observational study, we investigated the association between antiplatelet therapy and cerebral microbleeds (CMBs) in community-based participants without stroke. The presence, count, and location of CMBs were evaluated by susceptibility weighted imaging. Antiplatelet therapy included aspirin use alone, clopidogrel use alone, cilostazol use alone, and dual antiplatelet therapy with aspirin and clopidogrel. We found that antiplatelet therapy was independently associated with CMBs at any location, particularly lobar CMBs, and aspirin use was a risk factor for any CMB and lobar CMBs. Our study suggests that optimizing antiplatelet treatment strategies in stroke-free population may decrease the risk of CMBs.
This abstract and the presentation materials are available to members only;
a login is required.